Clinical Trials Browser

Phase 1/2 × Amyloidosis × In Situ Hybridization, Fluorescence × Clear all

NCT05486481 2025-03-06

Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14) (ALTITUDE)

Phase 1/2 Withdrawn

Immunoglobulin Light-chain Amyloidosis, Amyloidosis